Skip to main content
Premium Trial:

Request an Annual Quote

NIH Seeks Infection-linked Cancer Signatures

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – The National Institutes of Health will fund research that seeks to discover biomarkers for cancers that may be caused by the presence of infectious agents, such as viruses or bacteria.

Supported by the National Cancer Institute and the National Institute of Dental and Craniofacial Research, the program will fund scientists seeking to identify molecular signatures that distinguish individuals with infectious agents who are at high risk of developing cancer or that can detect early stages of cancer in infected individuals.

The grants will be supported under R01 grants that will not have specific funding amounts and under R21 grants that will provide up to $275,000 over a two-year period.

The goal of this program is to increase knowledge about infection-associated cancers, to find ways to identify individuals who are at high risk of developing such cancers, and to detect early stage cancers in people in that population.

"Infection-associated cancers are increasing at an alarming rate," and roughly 15 percent of cancers worldwide are linked to viral and bacterial agents and other pathogens, NIH stated in its funding announcement.

However, though the number of people infected by a pathogen may be very high, "only a minor proportion ever develops cancer," NIH stated. "For example, 10 million women in the US have cervical human papillomavirus infections, but only 15 thousand develop cancers. In addition, only 1 percent of Helicobacter pylori-infected persons will develop gastric cancer," NIH continued.

Molecular signatures that could distinguish which infected individuals are at high risk of developing cancer or that can detect early stages of cancer in infected people could lessen the danger of death from these malignancies.

These grants will fund research to discover molecular profiles of normal, precancerous, and cancerous lesions following infection and markers found in body fluids from infected individuals. The studies also may analyze molecular profiles to determine whether a single biomarker, a panel of markers, or molecular patterns can be used to determine which infected individuals are at risk of developing cancer, and potentially used to identify targets for cancer prevention and treatment.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.